CLINICAL STUDIES
A comparison of the acute hemodynamic effects of inhaled nitric oxide and aerosolized iloprost in primary pulmonary hypertension
Marius M. Hoeper, MD*,
Horst Olschewski, MD ,
Hossein A. Ghofrani, MD ,
Heinrike Wilkens, MD ,
Joerg Winkler, MD ,
Mathias M. Borst, MD||,
Jost Niedermeyer, MD*,
Helmut Fabel, MD*,
Werner Seeger, MD the German PPH Study Group¶
* Departments of Pulmonary Medicine, Hannover Medical School, Hannover, Germany
Department of Internal Medicine, Justus Liebig University, Giessen, Germany
Department of Pulmonary Medicine, University of the Saarland, Homburg, Germany
Department of Internal Medicine, University of Leipzig, Heidelberg, Germany
|| Department of Internal Medicine, University of Heidelberg, Heidelberg, Germany
Manuscript received April 22, 1999;
revised manuscript received July 23, 1999,
accepted September 13, 1999.
Reprint requests and correspondence: Dr. Marius M. Hoeper, Department of Pulmonary Medicine, Hannover Medical School, 30623 Hannover, Germany KMHoeper{at}AOL.com
OBJECTIVE
We sought to compare the acute hemodynamic effects of inhaled nitric oxide (NO) and aerosolized iloprost in primary pulmonary hypertension (PPH).
BACKGROUND
Inhalation of the stable prostacyclin analogue iloprost has recently been described as a novel therapeutic strategy for PPH and may offer an alternative to continuous intravenous infusion of prostacyclin or inhalation of NO.
METHODS
During right heart catheterization, 35 patients with PPH sequentially inhaled 40 ppm of NO and 14 to 17 µg of iloprost, and the effects on hemodynamics and blood gases were monitored.
RESULTS
Both NO and iloprost caused significant increases in cardiac output, mixed-venous oxygen saturation and stroke volume as well as significant decreases in pulmonary artery pressure and pulmonary vascular resistance, whereas only inhaled iloprost significantly increased the arterial PO2 (p = 0.01). Compared with inhaled NO, aerosolized iloprost was more effective in reducing pulmonary artery pressure (8.3 ± 7.5 mm Hg vs. 4.3 ± 8.8 mm Hg; p = 0.0001) and the pulmonary vascular resistance (447 ± 340 dynes·s·cm5 vs. 183 ± 305 dyne·s·cm5; p < 0.0001). Furthermore, aerosolized iloprost caused a significantly greater increase of the cardiac output compared with NO (+0.7 ± 0.6 liter/min vs. +0.3 ± 0.4 liter/min; p = 0.0002) and had a more pronounced effect on the mixed-venous oxygen saturation (p = 0.003).
CONCLUSIONS
During acute drug testing, aerosolized iloprost was more potent than inhaled NO as a pulmonary vasodilator in PPH at the doses used in this study.
|
Abbreviations and Acronyms
| | CO | = cardiac output | | NO | = nitric oxide | | NYHA | = New York Heart Association | | PCWP | = pulmonary capillary wedge pressure | | PGI2 | = prostacyclin | | PPH | = primary pulmonary hypertension |
|
This article has been cited by other articles:

|
 |

|
 |
 
C. F. Opitz and L. J. Rubin
Acute vasodilator testing in idiopathic pulmonary arterial hypertension: must we take NO for the answer?
Eur. Respir. J.,
June 1, 2009;
33(6):
1247 - 1249.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z-C. Jing, X. Jiang, Z-Y. Han, X-Q. Xu, Y. Wang, Y. Wu, H. Lv, C-R. Ma, Y-J. Yang, and J-L. Pu
Iloprost for pulmonary vasodilator testing in idiopathic pulmonary arterial hypertension
Eur. Respir. J.,
June 1, 2009;
33(6):
1354 - 1360.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, M. W. Wilkins, and S. Rich
Uncertainties in the Diagnosis and Treatment of Pulmonary Arterial Hypertension
Circulation,
September 9, 2008;
118(11):
1195 - 1201.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Y.-J. Lai, S. S. Pullamsetti, E. Dony, N. Weissmann, G. Butrous, G.-A. Banat, H. A. Ghofrani, W. Seeger, F. Grimminger, and R. T. Schermuly
Role of the Prostanoid EP4 Receptor in Iloprost-mediated Vasodilatation in Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
July 15, 2008;
178(2):
188 - 196.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. D. Ivy, A. K. Doran, K. J. Smith, G. B. Mallory Jr, M. Beghetti, R. J. Barst, D. Brady, Y. Law, D. Parker, L. Claussen, et al.
Short- and Long-Term Effects of Inhaled Iloprost Therapy in Children With Pulmonary Arterial Hypertension
J. Am. Coll. Cardiol.,
January 15, 2008;
51(2):
161 - 169.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
J. D. Edelman
Clinical Presentation, Differential Diagnosis, and Vasodilator Testing of Pulmonary Hypertension
Seminars in Cardiothoracic and Vascular Anesthesia,
June 1, 2007;
11(2):
110 - 118.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hoeper, S. H. Lee, R. Voswinckel, M. Palazzini, X. Jais, A. Marinelli, R. J. Barst, H. A. Ghofrani, Z.-C. Jing, C. Opitz, et al.
Complications of Right Heart Catheterization Procedures in Patients With Pulmonary Hypertension in Experienced Centers
J. Am. Coll. Cardiol.,
December 19, 2006;
48(12):
2546 - 2552.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, N. Weissmann, R. T. Schermuly, W. Seeger, and F. Grimminger
Hypoxia- and non-hypoxia-related pulmonary hypertension - Established and new therapies
Cardiovasc Res,
October 1, 2006;
72(1):
30 - 40.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Ulrich, M. Fischler, R. Speich, V. Popov, and M. Maggiorini
Chronic thromboembolic and pulmonary arterial hypertension share acute vasoreactivity properties.
Chest,
September 1, 2006;
130(3):
841 - 846.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kramm, B. Eberle, S. Guth, and E. Mayer
Inhaled iloprost to control residual pulmonary hypertension following pulmonary endarterectomy
Eur. J. Cardiothorac. Surg.,
December 1, 2005;
28(6):
882 - 888.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
B. L. Sandifer, K. L. Brigham, E. C. Lawrence, D. Mottola, C. Cuppels, and R. E. Parker
Potent effects of aerosol compared with intravenous treprostinil on the pulmonary circulation
J Appl Physiol,
December 1, 2005;
99(6):
2363 - 2368.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rubin and D. B. Badesch
Evaluation and Management of the Patient with Pulmonary Arterial Hypertension
Ann Intern Med,
August 16, 2005;
143(4):
282 - 292.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.-J. Seyfarth, H. Pankau, S. Hammerschmidt, J. Schauer, H. Wirtz, and J. Winkler
Bosentan Improves Exercise Tolerance and Tei Index in Patients With Pulmonary Hypertension and Prostanoid Therapy
Chest,
August 1, 2005;
128(2):
709 - 713.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Schermuly, H. Yilmaz, H. A. Ghofrani, K. Woyda, S. Pullamsetti, A. Schulz, T. Gessler, R. Dumitrascu, N. Weissmann, F. Grimminger, et al.
Inhaled Iloprost Reverses Vascular Remodeling in Chronic Experimental Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
August 1, 2005;
172(3):
358 - 363.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. E Baker and R. H. Hockman
Inhaled Iloprost in Pulmonary Arterial Hypertension
Ann. Pharmacother.,
July 1, 2005;
39(7):
1265 - 1274.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Sitbon, M. Humbert, X. Jais, V. Ioos, A. M. Hamid, S. Provencher, G. Garcia, F. Parent, P. Herve, and G. Simonneau
Long-Term Response to Calcium Channel Blockers in Idiopathic Pulmonary Arterial Hypertension
Circulation,
June 14, 2005;
111(23):
3105 - 3111.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Bossone, B. D. Bodini, A. Mazza, and L. Allegra
Pulmonary Arterial Hypertension: The Key Role of Echocardiography
Chest,
May 1, 2005;
127(5):
1836 - 1843.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Nagaoka, K. A. Fagan, S. A. Gebb, K. G. Morris, T. Suzuki, H. Shimokawa, I. F. McMurtry, and M. Oka
Inhaled Rho Kinase Inhibitors Are Potent and Selective Vasodilators in Rat Pulmonary Hypertension
Am. J. Respir. Crit. Care Med.,
March 1, 2005;
171(5):
494 - 499.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Task Force members, N. Galie, A. Torbicki, R. Barst, P. Dartevelle, S. Haworth, T. Higenbottam, H. Olschewski, A. Peacock, G. Pietra, et al.
Guidelines on diagnosis and treatment of pulmonary arterial hypertension: The Task Force on Diagnosis and Treatment of Pulmonary Arterial Hypertension of the European Society of Cardiology
Eur. Heart J.,
December 2, 2004;
25(24):
2243 - 2278.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, R. Voswinckel, F. Reichenberger, H. Olschewski, P. Haredza, B. Karadas, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger
Differences in hemodynamic and oxygenation responses to three different phosphodiesterase-5 inhibitors in patients with pulmonary arterial hypertension: A randomized prospective study
J. Am. Coll. Cardiol.,
October 6, 2004;
44(7):
1488 - 1496.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Badesch, S. H. Abman, G. S. Ahearn, R. J. Barst, D. C. McCrory, G. Simonneau, and V. V. McLaughlin
Medical Therapy For Pulmonary Arterial Hypertension: ACCP Evidence-Based Clinical Practice Guidelines
Chest,
July 1, 2004;
126(1_suppl):
35S - 62S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. B. Badesch, V. V. McLaughlin, M. Delcroix, C. Vizza, H. Olschewski, O. Sitbon, and R. J. Barst
Prostanoid therapy for pulmonary arterial hypertension
J. Am. Coll. Cardiol.,
June 16, 2004;
43(12_Suppl_S):
56S - 61S.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H.A. Ghofrani, G. Friese, T. Discher, H. Olschewski, R.T. Schermuly, N. Weissmann, W. Seeger, F. Grimminger, and J. Lohmeyer
Inhaled iloprost is a potent acute pulmonary vasodilator in HIV-related severe pulmonary hypertension
Eur. Respir. J.,
February 1, 2004;
23(2):
321 - 326.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. H. Leuchte, M. Schwaiblmair, R. A. Baumgartner, C. F. Neurohr, T. Kolbe, and J. Behr
Hemodynamic Response to Sildenafil, Nitric Oxide, and Iloprost in Primary Pulmonary Hypertension
Chest,
February 1, 2004;
125(2):
580 - 586.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. Wauthy, S. Abdel Kafi, W. J. Mooi, R. Naeije, and S. Brimioulle
Inhaled nitric oxide versus prostacyclin in chronic shunt-induced pulmonary hypertension
J. Thorac. Cardiovasc. Surg.,
November 1, 2003;
126(5):
1434 - 1441.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Olschewski, B. Rohde, J. Behr, R. Ewert, T. Gessler, H. A. Ghofrani, and T. Schmehl
Pharmacodynamics and Pharmacokinetics of Inhaled Iloprost, Aerosolized by Three Different Devices, in Severe Pulmonary Hypertension
Chest,
October 1, 2003;
124(4):
1294 - 1304.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Kramm, B. Eberle, F. Krummenauer, S. Guth, H. Oelert, and E. Mayer
Inhaled iloprost in patients with chronic thromboembolic pulmonary hypertension: effects before and after pulmonary thromboendarterectomy
Ann. Thorac. Surg.,
September 1, 2003;
76(3):
711 - 718.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. Langer, W. Wilhelm, D. Tscholl, R. Schramm, H. Lausberg, O. Wendler, and H.-J. Schafers
Intraoperative inhalation of the long-acting prostacyclin analog iloprost for pulmonary hypertension
J. Thorac. Cardiovasc. Surg.,
September 1, 2003;
126(3):
874 - 875.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.M. Hoeper, N. Taha, A. Bekjarova, R. Gatzke, and E. Spiekerkoetter
Bosentan treatment in patients with primary pulmonary hypertension receiving nonparenteral prostanoids
Eur. Respir. J.,
August 1, 2003;
22(2):
330 - 334.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, F. Rose, R. T. Schermuly, H. Olschewski, R. Wiedemann, A. Kreckel, N. Weissmann, S. Ghofrani, B. Enke, W. Seeger, et al.
Oral sildenafil as long-term adjunct therapy to inhaled iloprost in severe pulmonary arterial hypertension
J. Am. Coll. Cardiol.,
July 2, 2003;
42(1):
158 - 164.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
O. Sitbon, D. B. Badesch, R. N. Channick, A. Frost, I. M. Robbins, G. Simonneau, V. F. Tapson, and L. J. Rubin
Effects of the Dual Endothelin Receptor Antagonist Bosentan in Patients With Pulmonary Arterial Hypertension: A 1-Year Follow-up Study
Chest,
July 1, 2003;
124(1):
247 - 254.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sablotzki, E. Czeslick, E. Gruenig, I. Friedrich, S. Schubert, J. Borgermann, and T. Hentschel
First experiences with the stable prostacyclin analog iloprost in the evaluation of heart transplant candidates with increased pulmonary vascular resistance
J. Thorac. Cardiovasc. Surg.,
April 1, 2003;
125(4):
960 - 962.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
C.F Opitz, R Wensel, M Bettmann, R Schaffarczyk, M Linscheid, R Hetzer, and R Ewert
Assessment of the vasodilator response in primary pulmonary hypertension: Comparing prostacyclin and iloprost administered by either infusion or inhalation
Eur. Heart J.,
February 2, 2003;
24(4):
356 - 365.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Sablotzki, T. Hentschel, E. Gruenig, S. Schubert, I. Friedrich, J. Muhling, M. G. Dehne, and E. Czeslick
Hemodynamic effects of inhaled aerosolized iloprost and inhaled nitric oxide in heart transplant candidates with elevated pulmonary vascular resistance
Eur. J. Cardiothorac. Surg.,
November 1, 2002;
22(5):
746 - 752.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. Schermuly, A. Schulz, H. A. Ghofrani, A. Meidow, F. Rose, A. Roehl, N. Weissmann, M. Hildebrand, J. Kurz, F. Grimminger, et al.
Pharmacokinetics and Metabolism of Infused versus Inhaled Iloprost in Isolated Rabbit Lungs
J. Pharmacol. Exp. Ther.,
November 1, 2002;
303(2):
741 - 745.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
N. Galie, A. Manes, and A. Branzi
The new clinical trials on pharmacological treatment in pulmonary arterial hypertension
Eur. Respir. J.,
October 1, 2002;
20(4):
1037 - 1049.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
E. Spiekerkoetter, H. Fabel, and M.M. Hoeper
Effects of inhaled salbutamol in primary pulmonary hypertension
Eur. Respir. J.,
September 1, 2002;
20(3):
524 - 528.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.M. Hoeper, E. Spiekerkoetter, V. Westerkamp, R. Gatzke, and H. Fabel
Intravenous iloprost for treatment failure of aerosolised iloprost in pulmonary arterial hypertension
Eur. Respir. J.,
August 1, 2002;
20(2):
339 - 343.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Olschewski, G. Simonneau, N. Galie, T. Higenbottam, R. Naeije, L. J. Rubin, S. Nikkho, R. Speich, M. M. Hoeper, J. Behr, et al.
Inhaled Iloprost for Severe Pulmonary Hypertension
N. Engl. J. Med.,
August 1, 2002;
347(5):
322 - 329.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F J Meyer, R Ewert, M M Hoeper, H Olschewski, J Behr, J Winkler, H Wilkens, C Breuer, W Kubler, and M M Borst
Peripheral airway obstruction in primary pulmonary hypertension
Thorax,
June 1, 2002;
57(6):
473 - 476.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. C. Blumberg, G. A. J. Riegger, and M. Pfeifer
Hemodynamic Effects of Aerosolized Iloprost in Pulmonary Hypertension at Rest and During Exercise*
Chest,
May 1, 2002;
121(5):
1566 - 1571.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hoeper, N. Galie, G. Simonneau, and L. J. Rubin
New Treatments for Pulmonary Arterial Hypertension
Am. J. Respir. Crit. Care Med.,
May 1, 2002;
165(9):
1209 - 1216.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. A. Ghofrani, R. Wiedemann, F. Rose, H. Olschewski, R. T. Schermuly, N. Weissmann, W. Seeger, and F. Grimminger
Combination Therapy with Oral Sildenafil and Inhaled Iloprost for Severe Pulmonary Hypertension
Ann Intern Med,
April 2, 2002;
136(7):
515 - 522.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Schulz, G. Baseler, H.A. Ghofrani, F. Grimminger, H. Olschewski, and W. Seeger
Nocturnal periodic breathing in primary pulmonary hypertension
Eur. Respir. J.,
April 1, 2002;
19(4):
658 - 663.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M.M. Hoeper
Pulmonary hypertension in collagen vascular disease
Eur. Respir. J.,
March 1, 2002;
19(3):
571 - 576.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. S. Maxey, C. D. Smith, J. A. Kern, C. G. Tribble, D. R. Jones, I. L. Kron, and I. K. Crosby
Beneficial effects of inhaled nitric oxide in adult cardiac surgical patients
Ann. Thorac. Surg.,
February 1, 2002;
73(2):
529 - 533.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. T. SCHERMULY, E. KRUPNIK, H. TENOR, C. SCHUDT, N. WEISSMANN, F. ROSE, F. GRIMMINGER, W. SEEGER, D. WALMRATH, and H. A. GHOFRANI
Coaerosolization of Phosphodiesterase Inhibitors Markedly Enhances the Pulmonary Vasodilatory Response to Inhaled Iloprost in Experimental Pulmonary Hypertension . Maintenance of Lung Selectivity
Am. J. Respir. Crit. Care Med.,
November 1, 2001;
164(9):
1694 - 1700.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W Budts, N Van Pelt, H Gillyns, M Gewillig, F Van de Werf, and S Janssens
Residual pulmonary vasoreactivity to inhaled nitric oxide in patients with severe obstructive pulmonary hypertension and Eisenmenger syndrome
Heart,
November 1, 2001;
86(5):
553 - 558.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
R. Wiedemann, H. A. Ghofrani, N. Weissmann, R. Schermuly, K. Quanz, F. Grimminger, W. Seeger, and H. Olschewski
Atrial natriuretic peptide in severe primary and nonprimary pulmonary hypertension: Response to iloprost inhalation
J. Am. Coll. Cardiol.,
October 1, 2001;
38(4):
1130 - 1136.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Wilkens, A. Guth, J. Konig, N. Forestier, B. Cremers, B. Hennen, M. Bohm, and G. W. Sybrecht
Effect of Inhaled Iloprost Plus Oral Sildenafil in Patients With Primary Pulmonary Hypertension
Circulation,
September 11, 2001;
104(11):
1218 - 1222.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. C. Rimensberger, I. Spahr-Schopfer, M. Berner, E. Jaeggi, A. Kalangos, B. Friedli, and M. Beghetti
Inhaled Nitric Oxide Versus Aerosolized Iloprost in Secondary Pulmonary Hypertension in Children With Congenital Heart Disease : Vasodilator Capacity and Cellular Mechanisms
Circulation,
January 30, 2001;
103(4):
544 - 548.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Machherndl, M. Kneussl, H. Baumgartner, B. Schneider, V. Petkov, P. Schenk, and I.M. Lang
Long-term treatment of pulmonary hypertension with aerosolized iloprost
Eur. Respir. J.,
January 1, 2001;
17(1):
8 - 13.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
T. Gessler, T. Schmehl, M.M. Hoeper, F. Rose, H.A. Ghofrani, H. Olschewski, F. Grimminger, and W. Seeger
Ultrasonic versus jet nebulization of iloprost in severe pulmonary hypertension
Eur. Respir. J.,
January 1, 2001;
17(1):
14 - 19.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Archer and S. Rich
Primary Pulmonary Hypertension : A Vascular Biology and Translational Research "Work in Progress"
Circulation,
November 28, 2000;
102(22):
2781 - 2791.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. Gorenflo
Calculation of resistance to pulmonary perfusion
J. Am. Coll. Cardiol.,
October 1, 2000;
36(4):
1440 - 1440.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
M. M. Hoeper, M. Schwarze, S. Ehlerding, A. Adler-Schuermeyer, E. Spiekerkoetter, J. Niedermeyer, M. Hamm, and H. Fabel
Long-Term Treatment of Primary Pulmonary Hypertension with Aerosolized Iloprost, a Prostacyclin Analogue
N. Engl. J. Med.,
June 22, 2000;
342(25):
1866 - 1870.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
H. Olschewski, H. A. Ghofrani, T. Schmehl, J. Winkler, H. Wilkens, M. M. Hoper, J. Behr, F.-X. Kleber, W. Seeger, and for the German PPH Study Group*
Inhaled Iloprost To Treat Severe Pulmonary Hypertension: An Uncontrolled Trial
Ann Intern Med,
March 21, 2000;
132(6):
435 - 443.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|